伊伐布雷定在儿童心血管疾病中的应用进展

蒋露; 孙慧超

doi:10.7499/j.issn.1008-8830.2401072

PDF(592 KB)

HTML

中国当代儿科杂志 ›› 2024, Vol. 26 ›› Issue (7) : 782-788. DOI: 10.7499/j.issn.1008-8830.2401072

综述

伊伐布雷定在儿童心血管疾病中的应用进展

蒋露, 孙慧超

作者信息 +

Research progress in the application of ivabradine in children with cardiovascular diseases

JIANG Lu, SUN Hui-Chao

Author information +

文章历史 +

摘要

伊伐布雷定作为特异性I_f电流抑制剂，因其在降低心率的同时不影响心肌收缩力和血压，已广泛应用于成人慢性心力衰竭的治疗，并且在多种快速性心律失常中亦展现出良好的治疗效果。但伊伐布雷定在儿童心血管疾病的应用还有很多限制，该文就目前国内外关于伊伐布雷定治疗儿童心血管疾病的研究进展进行综述，以期为儿童心血管医生提供指导。

Abstract

Ivabradine, as a specific I_f current inhibitor, has been widely used in the treatment of chronic heart failure in adults due to its ability to reduce heart rate without affecting myocardial contractility and blood pressure. It has also shown good effects in various types of tachyarrhythmias. However, the application of ivabradine in pediatric cardiovascular diseases still faces many limitations. This article reviews the current research progress on the use of ivabradine in treating pediatric cardiovascular diseases both domestically and internationally, aiming to provide guidance for pediatric cardiologists. Citation:Chinese Journal of Contemporary Pediatrics, 2024, 26(7): 782-788

导出引用

蒋露, 孙慧超. 伊伐布雷定在儿童心血管疾病中的应用进展[J]. 中国当代儿科杂志. 2024, 26(7): 782-788 https://doi.org/10.7499/j.issn.1008-8830.2401072

JIANG Lu, SUN Hui-Chao. Research progress in the application of ivabradine in children with cardiovascular diseases[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(7): 782-788 https://doi.org/10.7499/j.issn.1008-8830.2401072

参考文献

1 中国医师协会心力衰竭专业委员会, 国家心血管病专家委员会心力衰竭专业委员会, 中华心力衰竭和心肌病杂志编辑委员. 伊伐布雷定临床应用中国专家共识[J]. 中华心力衰竭和心肌病杂志, 2020, 4(2): 84-91. DOI: 10.3760/cma.j.cn101460-20200529-00055.
2 Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. J Card Fail, 2017, 23(8): 628-651. PMID: 28461259. DOI: 10.1016/j.cardfail.2017.04.014.
3 徐腾琪, 王小飞. 伊伐布雷定在心律失常中的研究进展[J]. 中国新药杂志, 2023, 32(9): 911-915. DOI: 10.3969/j.issn.1003-3734.2023.09.008.
4 Ho JE, Larson MG, Ghorbani A, et al. Long-term cardiovascular risks associated with an elevated heart rate: the Framingham Heart Study[J]. J Am Heart Assoc, 2014, 3(3): e000668. PMID: 24811610. PMCID: PMC4309047. DOI: 10.1161/JAHA.113.000668.
5 Swedberg K, Komajda M, B?hm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study[J]. Lancet, 2010, 376(9744): 875-885. PMID: 20801500. DOI: 10.1016/S0140-6736(10)61198-1.
6 国家卫生计生委合理用药专家委员会, 中国药师协会. 心力衰竭合理用药指南（第2版）[J]. 中国医学前沿杂志（电子版）, 2019, 11(7): 1-78. DOI: 10.12037/YXQY.2019.07-01.
7 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. PMID: 30369168. DOI: 10.3760/cma.j.issn.0253-3758.2018.10.004.
8 Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2022, 79(17): e263-e421. PMID: 35379503. DOI: 10.1016/j.jacc.2021.12.012.
9 Bonnet D, Berger F, Jokinen E, et al. Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure[J]. J Am Coll Cardiol, 2017, 70(10): 1262-1272. PMID: 28859790. DOI: 10.1016/j.jacc.2017.07.725.
10 中华医学会儿科学分会心血管学组, 中国医师协会心血管内科医师分会儿童心血管专业委员会, 中华儿科杂志编辑委员会. 儿童心力衰竭诊断和治疗建议（2020年修订版）[J]. 中华儿科杂志, 2021, 59(2): 84-94. PMID: 33548953. DOI: 10.3760/cma.j.cn112140-20200619-00737.
11 Ahmed A, Pothineni NVK, Charate R, et al. Inappropriate sinus tachycardia: etiology, pathophysiology, and management: JACC review topic of the week[J]. J Am Coll Cardiol, 2022, 79(24): 2450-2462. PMID: 35710196. DOI: 10.1016/j.jacc.2022.04.019.
12 Ugan Atik S, Dedeo?lu R, Koka A, et al. Our experience in the diagnosis and treatment of postural orthostatic tachycardia syndrome, vasovagal syncope, and inappropriate sinus tachycardia in children[J]. Turk Kardiyol Dern Ars, 2017, 45(3): 227-234. PMID: 28429690. DOI: 10.5543/tkda.2017.36517.
13 Buchhorn R, Baumann C, Gündogdu S, et al. Diagnosis and management of an inappropriate sinus tachycardia in adolescence based upon a Holter ECG: a retrospective analysis of 479 patients[J]. PLoS One, 2020, 15(8): e0238139. PMID: 32845894. PMCID: PMC7449400. DOI: 10.1371/journal.pone.0238139.
14 Hou CR, Olshansky B, Cortez D, et al. Inappropriate sinus tachycardia: an examination of existing definitions[J]. Europace, 2022, 24(10): 1655-1664. PMID: 35851637. DOI: 10.1093/europace/euac057.
15 Shabtaie SA, Witt CM, Asirvatham SJ. Efficacy of medical and ablation therapy for inappropriate sinus tachycardia: a single-center experience[J]. J Cardiovasc Electrophysiol, 2021, 32(4): 1053-1061. PMID: 33566447. DOI: 10.1111/jce.14942.
16 Mathew ST, Po SS, Thadani U. Inappropriate sinus tachycardia-symptom and heart rate reduction with ivabradine: a pooled analysis of prospective studies[J]. Heart Rhythm, 2018, 15(2): 240-247. PMID: 29017929. DOI: 10.1016/j.hrthm.2017.10.004.
17 Ali M, Haji AQ, Kichloo A, et al. Inappropriate sinus tachycardia: a review[J]. Rev Cardiovasc Med, 2021, 22(4): 1331-1339. PMID: 34957774. DOI: 10.31083/j.rcm2204139.
18 Martino A, Rebecchi M, Sette A, et al. Ivabradine versus bisoprolol in the treatment of inappropriate sinus tachycardia: a long-term follow-up study[J]. J Cardiovasc Med (Hagerstown), 2021, 22(11): 892-900. PMID: 34747925. DOI: 10.2459/JCM.0000000000001203.
19 Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2020, 41(5): 655-720. PMID: 31504425. DOI: 10.1093/eurheartj/ehz467.
20 Romeo E, Grimaldi N, Sarubbi B, et al. A pediatric case of cardiomyopathy induced by inappropriate sinus tachycardia: efficacy of ivabradine[J]. Pediatr Cardiol, 2011, 32(6): 842-845. PMID: 21479666. DOI: 10.1007/s00246-011-9964-1.
21 廖莹. 儿童体位性心动过速综合征诊治策略[J]. 临床儿科杂志, 2022, 40(7): 488-493. DOI: 10.12372/jcp.2022.22e0412.
22 Mar PL, Raj SR. Postural orthostatic tachycardia syndrome: mechanisms and new therapies[J]. Annu Rev Med, 2020, 71: 235-248. PMID: 31412221. DOI: 10.1146/annurev-med-041818-011630.
23 Taub PR, Zadourian A, Lo HC, et al. Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome[J]. J Am Coll Cardiol, 2021, 77(7): 861-871. PMID: 33602468. DOI: 10.1016/j.jacc.2020.12.029.
24 Delle Donne G, Rosés Noguer F, Till J, et al. Ivabradine in postural orthostatic tachycardia syndrome: preliminary experience in children[J]. Am J Cardiovasc Drugs, 2018, 18(1): 59-63. PMID: 29027608. DOI: 10.1007/s40256-017-0248-x.
25 Towheed A, Nesheiwat Z, Mangi MA, et al. Ivabradine in children with postural orthostatic tachycardia syndrome: a retrospective study[J]. Cardiol Young, 2020, 30(7): 975-979. PMID: 32498748. DOI: 10.1017/S1047951120001341.
26 江河, 李小梅, 李梅婷, 等. 儿童局灶性房性心动过速125例临床特征及射频消融效果分析[J]. 中华儿科杂志, 2020, 58(11): 900-904. PMID: 33120461. DOI: 10.3760/cma.j.cn112140-20200308-00199.
27 Bohora S, Lokhandwala Y, Parekh P, et al. Reversal of tachycardiomyopathy due to left atrial tachycardia by ivabradine[J]. J Cardiovasc Electrophysiol, 2011, 22(3): 340-342. PMID: 20653812. DOI: 10.1111/j.1540-8167.2010.01860.x.
28 Banavalikar B, Shenthar J, Padmanabhan D, et al. Clinical and electrophysiological correlates of incessant ivabradine-sensitive atrial tachycardia[J]. Circ Arrhythm Electrophysiol, 2019, 12(8): e007387. PMID: 31345093. DOI: 10.1161/CIRCEP.119.007387.
29 中国药学会医院药学专业委员会, 《伊伐布雷定临床与药学实践专家共识》编写组. 伊伐布雷定临床与药学实践专家共识[J]. 中国医院药学杂志, 2021, 41(10): 979-990. DOI: 10.13286/j.1001-5213.2021.10.01.
30 Cohen MI, Cohen JA, Shope C, et al. Ivabradine as a stabilising anti-arrhythmic agent for multifocal atrial tachycardia[J]. Cardiol Young, 2020, 30(6): 899-902. PMID: 32519627. DOI: 10.1017/S1047951120001195.
31 Xu X, Guo Y, Gao W, et al. Ivabradine monotherapy in pediatric patients with focal atrial tachycardia: a single-center study[J]. Eur J Pediatr, 2023, 182(5): 2265-2271. PMID: 36869903. DOI: 10.1007/s00431-023-04891-8.
32 徐欣怡, 郭颖, 刘廷亮, 等. 伊伐布雷定治疗儿童房性心动过速致心肌病一例[J]. 中华儿科杂志, 2021, 59(1): 64-66. PMID: 33397009. DOI: 10.3760/cma.j.cn112140-20200615-00623.
33 Tasci O, Karadeniz C. Ivabradine in a 15-day-old male neonate with refractory focal atrial tachycardia[J]. Pacing Clin Electrophysiol, 2023, 46(8): 924-927. PMID: 37428945. DOI: 10.1111/pace.14781.
34 Tolani D, Ramdat Misier NL, Alqahtani M, et al. Early experience with ivabradine for focal atrial tachycardia in pediatric patients with congenital heart disease[J]. Heart Rhythm, 2024, 21(1): 115-116. PMID: 37852564. DOI: 10.1016/j.hrthm.2023.10.013.
35 Gul O, Kafali HC, Ergul Y. Successful treatment of the focal ectopic atrial tachycardia in an infant with a single dose of ivabradin[J]. Cardiol Young, 2023, 33(9): 1750-1752. PMID: 36959114. DOI: 10.1017/S1047951123000409.
36 Karmegaraj B, Balaji S, Raju PN, et al. Tachycardia-induced cardiomyopathy secondary to incessant ectopic atrial tachycardia in two infants: potential new indication for early initiation of enteral ivabradine[J]. Ann Pediatr Cardiol, 2021, 14(3): 422-427. PMID: 34667421. PMCID: PMC8457284. DOI: 10.4103/apc.apc_37_21.
37 Sasikumar N, Kumar RK, Balaji S. Diagnosis and management of junctional ectopic tachycardia in children[J]. Ann Pediatr Cardiol, 2021, 14(3): 372-381. PMID: 34667411. PMCID: PMC8457265. DOI: 10.4103/apc.apc_35_21.
38 Dieks JK, Klehs S, Müller MJ, et al. Adjunctive ivabradine in combination with amiodarone: a novel therapy for pediatric congenital junctional ectopic tachycardia[J]. Heart Rhythm, 2016, 13(6): 1297-1302. PMID: 27216242. DOI: 10.1016/j.hrthm.2016.03.015.
39 Dasgupta S, Johnsrude C. Combination therapy of ivabradine with procainamide for the management of pediatric postoperative junctional ectopic tachycardia[J]. J Innov Card Rhythm Manag, 2023, 14(7): 5528-5532. PMID: 37492694. PMCID: PMC10364659. DOI: 10.19102/icrm.2023.14075.
40 Krishna MR, Kunde MF, Kumar RK, et al. Ivabradine in post-operative junctional ectopic tachycardia (JET): breaking new ground[J]. Pediatr Cardiol, 2019, 40(6): 1284-1288. PMID: 31317219. DOI: 10.1007/s00246-019-02149-5.
41 Al-Ghamdi S, Al-Fayyadh MI, Hamilton RM. Potential new indication for ivabradine: treatment of a patient with congenital junctional ectopic tachycardia[J]. J Cardiovasc Electrophysiol, 2013, 24(7): 822-824. PMID: 23373720. DOI: 10.1111/jce.12081.
42 Di Marco GM, De Nigris A, Pepe A, et al. Ivabradine-flecainide as breakthrough drug combination for congenital junctional ectopic tachycardia: a case report and literature review[J]. Pediatr Rep, 2021, 13(4): 624-631. PMID: 34842781. PMCID: PMC8629013. DOI: 10.3390/pediatric13040074.
43 Arvind B, Kothari SS, Juneja R, et al. Ivabradine versus amiodarone in the management of postoperative junctional ectopic tachycardia: a randomized, open-label, noninferiority study[J]. JACC Clin Electrophysiol, 2021, 7(8): 1052-1060. PMID: 33812837. DOI: 10.1016/j.jacep.2021.01.020.
44 Devaprasath S, Buddhavarapu S, Mariam S, et al. Ivabradine monotherapy in congenital junctional ectopic tachycardia[J]. Ann Pediatr Cardiol, 2022, 15(1): 61-63. PMID: 35847400. PMCID: PMC9280110. DOI: 10.4103/apc.apc_264_20.
45 Asfour SS, Al-Omran KA, Alodhaidan NA, et al. Ivabradine monotherapy for the treatment of congenital junctional ectopic tachycardia in a premature neonate[J]. J Pediatr Pharmacol Ther, 2021, 26(4): 414-417. PMID: 34035688. PMCID: PMC8139562. DOI: 10.5863/1551-6776-26.4.414.
46 Doesch AO, Mueller S, Erbel C, et al. Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study[J]. Drug Des Devel Ther, 2013, 7: 1323-1328. PMID: 24235815. PMCID: PMC3821694. DOI: 10.2147/DDDT.S53705.
47 Rivinius R, Helmschrott M, Rahm AK, et al. Five-year results of heart rate control with ivabradine or metoprolol succinate in patients after heart transplantation[J]. Clin Res Cardiol, 2022, 111(2): 141-153. PMID: 32572551. PMCID: PMC8816306. DOI: 10.1007/s00392-020-01692-z.
48 Ogawa Y, Urata S, Inuzuka R. Successful use of ivabradine in a 10-year-old patient with graft failure after heart transplantation[J]. Cardiol Young, 2023, 33(4): 649-651. PMID: 35864814. DOI: 10.1017/S1047951122002335.
49 王志军, 程艳超, 范旭芳, 等. 不同剂量伊伐布雷定治疗病毒性心肌炎患儿的临床疗效及安全性[J]. 儿科药学杂志, 2020, 26(7): 27-30. DOI: 10.13407/j.cnki.jpp.1672-108X.2020.07.009.
50 Guang-Yi C, Li-Sha G, Yue-Chun L. Role of heart rate reduction in the management of myocarditis[J]. Curr Pharm Des, 2018, 24(3): 365-378. PMID: 29332571. DOI: 10.2174/1381612824666180111105923.
51 Li-Sha G, Li L, De-Pu Z, et al. Ivabradine treatment reduces cardiomyocyte apoptosis in a murine model of chronic viral myocarditis[J]. Front Pharmacol, 2018, 9: 182. PMID: 29556195. PMCID: PMC5844961. DOI: 10.3389/fphar.2018.00182.
52 陈小霞, 程齐尧, 詹磊, 等. 伊伐布雷定对病毒性心肌炎大鼠Bcl-2基因启动子区甲基化及mRNA表达的影响[J]. 中西医结合心脑血管病杂志, 2021, 19(12): 1991-1995. DOI: 10.12102/j.issn.1672-1349.2021.12.007.
53 李岳春. 伊伐布雷定对延缓病毒性心肌炎向扩张型心肌病演变的作用及机制研究[D]. 苏州: 苏州大学, 2017.
54 Yue-Chun L, Guang-Yi C, Li-Sha G, et al. The protective effects of ivabradine in preventing progression from viral myocarditis to dilated cardiomyopathy[J]. Front Pharmacol, 2016, 7: 408. PMID: 27847478. PMCID: PMC5088506. DOI: 10.3389/fphar.2016.00408.
55 周沫. 不同剂量伊伐布雷定治疗病毒性心肌炎患儿的效果分析[J]. 中国医学创新, 2023, 20(12): 62-66. DOI: 10.3969/j.issn.1674-4985.2023.12.015.
56 Peigné S, Fouliard S, Decourcelle S, et al. Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment[J]. J Pharmacokinet Pharmacodyn, 2016, 43(1): 29-43. PMID: 26578442. DOI: 10.1007/s10928-015-9452-y.